1
|
Rocchigiani AM, Bertoldi L, Coradduzza E, Lostia G, Pintus D, Scivoli R, Cancedda MG, Fiori MS, Bechere R, Murtino AP, Pala G, Cardeti G, Macioccu S, Dettori MA, Pintore A, Ligios C, Puggioni G. Whole-Genome Sequencing of Two Canine Herpesvirus 1 (CaHV-1) Isolates and Clinicopathological Outcomes of Infection in French Bulldog Puppies. Viruses 2024; 16:209. [PMID: 38399985 PMCID: PMC10893542 DOI: 10.3390/v16020209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 01/22/2024] [Accepted: 01/29/2024] [Indexed: 02/25/2024] Open
Abstract
Canine herpesvirus 1 (CaHV-1) infects dogs, causing neonatal death and ocular, neurological, respiratory, and reproductive problems in adults. Although CaHV-1 is widespread in canine populations, only four studies have focused on the CaHV-1 whole genome. In such context, two CaHV-1 strains from both the kidney and spleen of 20-day-old deceased French Bulldog puppies were recently isolated in Sardinia, Italy. The extracted viral DNA underwent whole-genome sequencing using the Illumina MiSeq platform. The Italian CaHV-1 genomes were nearly identical (>99%), shared the same tree branch, and clustered near the ELAL-1 (MW353125) and BTU-1 (KX828242) strains, enlarging the completely separated clade discussed by Lewin et al., in 2020. This study aims to provide new insights on the evolution of the CaHV-1, based on high-resolution whole-genome phylogenetic analysis, and on its clinicopathological characterization during a fatal outbreak in puppies.
Collapse
Affiliation(s)
- Angela Maria Rocchigiani
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | | | - Elisabetta Coradduzza
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Giada Lostia
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Davide Pintus
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Rosario Scivoli
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Maria Giovanna Cancedda
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Mariangela Stefania Fiori
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Roberto Bechere
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Anna Pina Murtino
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Giovanni Pala
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Giusy Cardeti
- Istituto Zooprofilattico Sperimentale del Lazio e della Toscana M. Aleandri, 00178 Roma, Italy;
| | - Simona Macioccu
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Maria Antonietta Dettori
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Antonio Pintore
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Ciriaco Ligios
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| | - Giantonella Puggioni
- Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy; (A.M.R.); (G.L.); (D.P.); (R.S.); (M.G.C.); (M.S.F.); (R.B.); (A.P.M.); (G.P.); (S.M.); (M.A.D.); (A.P.); (C.L.); (G.P.)
| |
Collapse
|
2
|
Giorgi J, Simon B, Destras G, Semanas Q, Ginevra C, Boyer T, Regue H, Billaud G, Ducastelle S, Ader F, Morfin F, Josset L, Frobert E. Novel UL23 and UL30 substitutions in HSV1 and HSV2 viruses related to polymorphism or drug resistance. Antiviral Res 2023:105672. [PMID: 37453453 DOI: 10.1016/j.antiviral.2023.105672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 07/11/2023] [Accepted: 07/12/2023] [Indexed: 07/18/2023]
Abstract
Data on herpes simplex virus (HSV) polymorphism as well as acyclovir (ACV) and foscarnet (FOS) resistance mutations are not exhaustive and may hinder accurate diagnosis by next-generation sequencing (NGS). Here, we report novel UL23 and UL30 substitutions for HSV1 and HSV2 identified in immunocompromised patients treated for hematological malignancies during the last 6 years of HSV resistance surveillance at the University Hospital of Lyon. For HSV1, 35 novel UL23 substitutions and 52 novel UL30 substitutions were identified. For HSV2, 2 novel UL23 substitutions and 12 novel UL30 substitutions were identified. These results allow to complete the database of HSV1 and HSV2 substitutions, related either to polymorphism or to ACV and FOS resistance.
Collapse
Affiliation(s)
- J Giorgi
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France
| | - B Simon
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France
| | - G Destras
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France; Université Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France
| | - Q Semanas
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France
| | - C Ginevra
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France; Laboratoire de Bactériologie, Centre National de Référence des Légionnelles, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France
| | - T Boyer
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France
| | - H Regue
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France
| | - G Billaud
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France
| | - S Ducastelle
- Service d'Hématologie Clinique, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 69495, Pierre-Bénite, France
| | - F Ader
- Université Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France; Service de Maladies Infectieuses et Tropicales, Groupement Hospitalier Nord, Hospices Civils de Lyon, France
| | - F Morfin
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; Université Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France
| | - L Josset
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, 69004, Lyon, France; Université Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France
| | - E Frobert
- Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004, Lyon, France; Université Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, 69008, Lyon, France.
| |
Collapse
|
3
|
Cai KQ, Shellhamer C, Akiyama T, Jensen LE. Pellino1 Restricts Herpes Simplex Virus Infections in the Epidermis and Dissemination to Sebaceous Glands. J Invest Dermatol 2023; 143:639-647.e2. [PMID: 36216205 PMCID: PMC10038864 DOI: 10.1016/j.jid.2022.09.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Revised: 08/19/2022] [Accepted: 09/08/2022] [Indexed: 11/06/2022]
Abstract
Nearly all adults are infected with one or more herpes viruses. The most common are herpes simplex virus (HSV)-1 and HSV-2, which upon reactivation can cause painful skin and mucosal erosions. Patients who are immune compromised often experience frequent, atypical, or chronic lesions and thus a greatly diminished QOL. Pellino1 is a ubiquitin ligase involved in IL-1 and toll-like receptor signaling; however, the role of Pellino1 in skin immunity against HSV is unknown. In this study, using the mouse-flank HSV-1 skin infection model, we show that Pellino1 has several critical functions during active viral replication. Peli1‒/‒ mice succumb more than wild-type mice to systemic disease and develop larger zosteriform skin lesions along affected dermatomes. In Pellino1-deficient mice, the virus spread extensively through the epidermis and follicular infundibulum into sebaceous glands where sebocytes were found positive for the virus. The latter did not appear to involve a shift in how the virus migrated through the nervous system. Immunohistochemistry revealed delayed recruitment of myeloid and T cells to the infected epidermis in Peli1‒/‒ mice. This was associated with decreased expression of the cytokine mRNAs Il1a, Il36b and 2610528A11Rik; the latter also known as Gpr15l. In conclusion, Pellino1 plays important roles in restricting viral dissemination, and the involved pathways may represent novel therapeutic targets in patients with frequent or chronic HSV infections.
Collapse
Affiliation(s)
- Kathy Q Cai
- Histopathology Facility, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA
| | - Caitlin Shellhamer
- Department of Microbiology, Immunology & Inflammation, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA
| | - Tasuku Akiyama
- Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, USA
| | - Liselotte E Jensen
- Department of Microbiology, Immunology & Inflammation, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA; Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania, USA.
| |
Collapse
|
4
|
Zhong H, Qin F, Ren Y, Li X, Hou L, Gu S, Jin Y. Functional characterization of differentially expressed proteins coming from unisexual and bisexual infected Schistosoma japonicum female worms. Exp Parasitol 2023; 248:108504. [PMID: 36914063 DOI: 10.1016/j.exppara.2023.108504] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/09/2023] [Accepted: 03/10/2023] [Indexed: 03/14/2023]
Abstract
Schistosomiasis is an important zoonotic disease affecting up to 40 kinds of animals and is responsible for ∼250 million human cases per year. Due to the extensive use of praziquantel for the treatment of parasitic diseases, drug resistance has been reported. Consequently, novel drugs and effective vaccines are urgently needed for sustained control of schistosomiasis. Targeting reproductive development of Schistosoma japonicum could contribute to the control of schistosomiasis. In this study, five highly expressed proteins (S. japonicum large subunit ribosomal protein L7e, S. japonicum glutathione S-transferase class-mu 26 kDa isozyme, S. japonicum UDP-galactose-4-epimerase and two hypothetical proteins SjCAX70849 and SjCAX72486) in 18, 21, 23, and 25-day mature female worms compared to single-sex infected female worms were selected based on our previous proteomic analysis. Quantitative real-time polymerase chain reaction analysis and long-term interference with small interfering RNA were performed to identify the biological functions of these five proteins. The transcriptional profiles suggested that all five proteins participated in the maturation of S. japonicum. RNA interference against these proteins resulted in morphological changes to S. japonicum. The results of an immunoprotection assay revealed that immunization of mice with recombinant SjUL-30 and SjCAX72486 upregulated production of immunoglobulin G-specific antibodies. Collectively, the results demonstrated that these five differentially expressed proteins were vital to reproduction of S. japonicum and, thus, are potential candidate antigens for immune protection against schistosomiasis.
Collapse
Affiliation(s)
- Haoran Zhong
- National Reference Laboratory for Animal Schistosomiasis, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; Key Laboratory of Animal Parasitology of Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China
| | - Fanglin Qin
- National Reference Laboratory for Animal Schistosomiasis, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; Key Laboratory of Animal Parasitology of Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; College of Life Sciences, Shanghai Normal University, Shanghai, PR China
| | - Yuqi Ren
- National Reference Laboratory for Animal Schistosomiasis, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; Key Laboratory of Animal Parasitology of Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China
| | - Xiaochun Li
- National Reference Laboratory for Animal Schistosomiasis, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; Key Laboratory of Animal Parasitology of Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; College of Life Sciences, Shanghai Normal University, Shanghai, PR China
| | - Ling Hou
- National Reference Laboratory for Animal Schistosomiasis, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; Key Laboratory of Animal Parasitology of Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Shanxi, PR China
| | - Shaopeng Gu
- College of Animal Science and Veterinary Medicine, Shanxi Agricultural University, Shanxi, PR China
| | - Yamei Jin
- National Reference Laboratory for Animal Schistosomiasis, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China; Key Laboratory of Animal Parasitology of Ministry of Agriculture and Rural Affairs, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, PR China.
| |
Collapse
|
5
|
Lince KC, DeMario VK, Yang GT, Tran RT, Nguyen DT, Sanderson JN, Pittman R, Sanchez RL. A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV. Cureus 2023; 15:e35958. [PMID: 37041924 PMCID: PMC10082683 DOI: 10.7759/cureus.35958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2023] [Indexed: 03/11/2023] Open
Abstract
Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients, whether they are immunocompromised or not, deserve to have their infections clinically managed in a manner supported by comprehensive research. This review provides necessary information about treatment options for patients with resistant HSV infections and their providers.
Collapse
|
6
|
Khellaf L, Bouscarat F, Burrel S, Fidouh N, Hachon L, Bucau M, Lariven S, Boutolleau D, Joly V, Ghosn J, Le Pluart D, Thy M. Novel mutations in antiviral multiresistant HSV-2 genital lesion: A case report. J Med Virol 2022; 94:6122-6126. [PMID: 35973907 DOI: 10.1002/jmv.28070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 08/02/2022] [Accepted: 08/15/2022] [Indexed: 01/07/2023]
Abstract
HSV-2 antiviral resistance mainly occurs in immunocompromised patients and especially in HIV-positive individuals receiving long-term antiviral treatment. Those situations can be challenging as few alternatives are available for HSV infection management. To describe clinical and virological significance of two novel potential HSV-2 resistance mutations after treating an obese patient with a pseudotumoral genital HSV-related lesion. Consecutive different antiviral treatments were used: valacyclovir (VACV) then foscarnet (FOS) then topical cidofovir (CDV) and finally imiquimod. Under VACV, genotypic resistance testing revealed a novel mutation within viral thymidine kinase (TK, gene UL23) not previously reported but probably accounting for antiviral resistance: W89G, similar to W88R mutation reported in HSV-1 TK, known to be associated with ACV resistance for HSV-1. Under FOS, while initial mutations were still present, a second genotypic resistance testing performed on persisting lesions showed a novel mutation within viral DNA polymerase (DNA pol, gene UL30): C625R. All three antivirals used in this case are small molecules and pharmacokinetics of VACV, FOS, and CDV have not been evaluated in animals and there are very few studies in human. As small molecules are poorly bound to proteins and distribution volume is increased in obese patients, there is risk of underdosage. This mechanism is suspected to be involved in emergence of resistance mutation and further data is needed to adapt, closely to patient profile, antiviral dosage. This report describes a chronic HSV-2 genital lesion, with resistance to current antivirals and novel mutations within viral TK and DNA pol which may confer antiviral resistance.
Collapse
Affiliation(s)
- Lucas Khellaf
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Fabrice Bouscarat
- Department of Dermatology, Hôpital Bichat, Université de Paris, Paris, France
| | - Sonia Burrel
- Department of Virology, Centre National de Référence Herpès virus, Hôpital Pitié-Salpétrière, Sorbonne Université, INSERM U1136, Institut Pierre Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - Nadhira Fidouh
- Department of Virology, Hôpital Bichat, Université de Paris, Paris, France
| | - Lorry Hachon
- Department of Pharmacy, Hôpital Bichat, Université de Paris, Paris, France
| | - Margot Bucau
- Department of Pathology, Hôpital Bichat, Université de Paris, Paris, France
| | - Sylvie Lariven
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - David Boutolleau
- Department of Virology, Centre National de Référence Herpès virus, Hôpital Pitié-Salpétrière, Sorbonne Université, INSERM U1136, Institut Pierre Louis d'épidémiologie et de santé publique (IPLESP), Paris, France
| | - Véronique Joly
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Jade Ghosn
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Diane Le Pluart
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| | - Michaël Thy
- Department of Infectious Diseases, Hôpital Bichat, Université de Paris, Paris, France
| |
Collapse
|
7
|
Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives. Biochem Pharmacol 2022; 206:115322. [DOI: 10.1016/j.bcp.2022.115322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 10/20/2022] [Accepted: 10/20/2022] [Indexed: 11/19/2022]
|
8
|
Majewska A, Mlynarczyk-Bonikowska B. 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs? Int J Mol Sci 2022; 23:ijms23073431. [PMID: 35408788 PMCID: PMC8998721 DOI: 10.3390/ijms23073431] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 03/10/2022] [Accepted: 03/18/2022] [Indexed: 01/17/2023] Open
Abstract
Herpes simplex virus types 1 and 2 HSV1 and 2, namely varicella-zoster VZV and cytomegalovirus CMV, are among the most common pathogens worldwide. They remain in the host body for life. The course of infection with these viruses is often asymptomatic or mild and self-limiting, but in immunocompromised patients, such as solid organ or bone marrow transplant recipients, the course can be very severe or even life-threatening. Unfortunately, in the latter group, the highest percentage of infections with strains resistant to routinely used drugs is observed. On the other hand, frequent recurrences of genital herpes can be a problem even in people with normal immunity. Genital herpes also increases the risk of acquiring sexually transmitted diseases, including HIV infection and, if present in pregnant women, poses a risk to the fetus and newborn. Even more frequently than herpes simplex, congenital infections can be caused by cytomegalovirus. We present the most important anti-herpesviral agents, the mechanisms of resistance to these drugs, and the associated mutations in the viral genome. Special emphasis was placed on newly introduced drugs such as maribavir and brincidofovir. We also briefly discuss the most promising substances in preclinical testing as well as immunotherapy options and vaccines currently in use and under investigation.
Collapse
Affiliation(s)
- Anna Majewska
- Department of Medical Microbiology, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland;
| | - Beata Mlynarczyk-Bonikowska
- Department of Dermatology, Immunodermatology and Venereology, Medical University of Warsaw, Koszykowa 82a, 02-008 Warsaw, Poland
- Correspondence: ; Tel.: +48-225021313
| |
Collapse
|
9
|
Roy S, Sukla S, De A, Biswas S. Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections. Sci Rep 2022; 12:1345. [PMID: 35079057 PMCID: PMC8789845 DOI: 10.1038/s41598-022-05188-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 01/05/2022] [Indexed: 11/09/2022] Open
Abstract
Herpes simplex virus (HSV) usually produces cytopathic effect (CPE) within 24-72 h post-infection (P.I.). Clinical isolates from recurrent HSV infections in patients on Acyclovir therapy were collected between 2016 and 2019 and tested in cell cultures for cytopathic effects and further in-depth characterization. Fourteen such isolates did not show any CPE in A549 or Vero cell lines even at 120 h P.I. However, these cultures remained positive for HSV-DNA after several passages. Sequence analysis revealed that the non-CPE isolates were all HSV-1. Analysis of the thymidine kinase gene from the isolates revealed several previously reported and two novel ACV-resistant mutations. Immunofluorescence and Western blot data revealed a low-level expression of the immediate early protein, ICP4. Late proteins like ICP5 or capsid protein, VP16 were almost undetectable in these isolates. AFM imaging revealed that the non-CPE viruses had structural deformities compared to wild-type HSV-1. Our findings suggest that these strains are manifesting an unusual phenomenon of being non-CPE herpesviruses with low level of virus protein expressions over several passages. Probably these HSV-1 isolates are evolving towards a more "cryptic" form to establish chronic infection in the host thereby unraveling yet another strategy of herpesviruses to evade the host immune system.
Collapse
Affiliation(s)
- Subrata Roy
- Infectious Diseases and Immunology Division, CSIR- Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Kolkata, West Bengal, 700032, India
| | - Soumi Sukla
- Infectious Diseases and Immunology Division, CSIR- Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Kolkata, West Bengal, 700032, India
- Department of Pharmacology and Toxicology, National Institute of Pharmaceuticals Education and Research, 168, Maniktala Main Road, Kolkata, West Bengal, India
| | - Abhishek De
- Department of Dermatology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
| | - Subhajit Biswas
- Infectious Diseases and Immunology Division, CSIR- Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, Kolkata, West Bengal, 700032, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh, India.
| |
Collapse
|
10
|
Giongo V, Falanga A, De Melo CPP, da Silva GB, Bellavita R, De-Simone SG, Paixão IC, Galdiero S. Antiviral Potential of Naphthoquinones Derivatives Encapsulated within Liposomes. Molecules 2021; 26:molecules26216440. [PMID: 34770849 PMCID: PMC8586984 DOI: 10.3390/molecules26216440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 10/13/2021] [Accepted: 10/22/2021] [Indexed: 11/16/2022] Open
Abstract
HSV infections, both type 1 and type 2, are among the most widespread viral diseases affecting people of all ages. Their symptoms could be mild, with cold sores up to 10 days of infection, blindness and encephalitis caused by HSV-1 affecting immunocompetent and immunosuppressed individuals. The severe effects derive from co-evolution with the host, resulting in immune evasion mechanisms, including latency and growing resistance to acyclovir and derivatives. An efficient alternative to controlling the spreading of HSV mutations is the exploitation of new drugs, and the possibility of enhancing their delivery through the encapsulation of drugs into nanoparticles, such as liposomes. In this work, liposomes were loaded with a series of 2-aminomethyl- 3-hydroxy-1,4-naphthoquinones derivatives with n-butyl (compound 1), benzyl (compound 2) and nitrobenzene (compound 3) substituents in the primary amine of naphthoquinone. They were previously identified to have significant inhibitory activity against HSV-1. All of the aminomethylnaphthoquinones derivatives encapsulated in the phosphatidylcholine liposomes were able to control the early and late phases of HSV-1 replication, especially those substituted with the benzyl (compound 2) and nitrobenzene (compound 3), which yields selective index values that are almost nine times more efficient than acyclovir. The growing interest of the industry in topical administration against HSV supports our choice of liposome as a drug carrier of aminomethylnaphthoquinones derivatives for formulations of in vivo pre-clinical assays.
Collapse
Affiliation(s)
- Viveca Giongo
- Programa de Pós-Graduação em Ciências e Biotecnologia, Department of Cellular and Molecular Biology, Biology Institute, Federal Fluminense University, Niterói 24020-141, Brazil; (C.P.P.D.M.); (S.G.D.-S.); (I.C.P.)
- Correspondence: (V.G.); (S.G.); Tel.: +552-130-829-025 (V.G.); +390-812-534-503 (S.G.)
| | - Annarita Falanga
- Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy;
| | - Camilly P. Pires De Melo
- Programa de Pós-Graduação em Ciências e Biotecnologia, Department of Cellular and Molecular Biology, Biology Institute, Federal Fluminense University, Niterói 24020-141, Brazil; (C.P.P.D.M.); (S.G.D.-S.); (I.C.P.)
| | - Gustavo B. da Silva
- Department of of Fundamental Chemistry, Federal Rural University of Rio de Janeiro, Seropédica 23897-000, Brazil;
| | - Rosa Bellavita
- Department of Pharmacy, University of Naples Federico II, 34102 Naples, Italy;
| | - Salvatore G. De-Simone
- Programa de Pós-Graduação em Ciências e Biotecnologia, Department of Cellular and Molecular Biology, Biology Institute, Federal Fluminense University, Niterói 24020-141, Brazil; (C.P.P.D.M.); (S.G.D.-S.); (I.C.P.)
- FIOCRUZ, Center for Technological Development in Health(CDTS)/National Institute of Science and Technology for Innovation in Neglected Diseases Populations (INCT-IDNP), Rio de Janeiro 21040-900, Brazil
| | - Izabel C. Paixão
- Programa de Pós-Graduação em Ciências e Biotecnologia, Department of Cellular and Molecular Biology, Biology Institute, Federal Fluminense University, Niterói 24020-141, Brazil; (C.P.P.D.M.); (S.G.D.-S.); (I.C.P.)
| | - Stefania Galdiero
- Department of Pharmacy, University of Naples Federico II, 34102 Naples, Italy;
- Correspondence: (V.G.); (S.G.); Tel.: +552-130-829-025 (V.G.); +390-812-534-503 (S.G.)
| |
Collapse
|
11
|
Gege C, Bravo FJ, Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, Burger-Kentischer A, Finkelmeier D, Hamprecht K, Grunwald T, Bernstein DI, Kleymann G. A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections. Sci Transl Med 2021; 13:13/598/eabf8668. [PMID: 34135112 DOI: 10.1126/scitranslmed.abf8668] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 04/26/2021] [Indexed: 12/17/2022]
Abstract
More than 50% of the world population is chronically infected with herpesviruses. Herpes simplex virus (HSV) infections are the cause of herpes labialis (cold sores), genital herpes, and sight-impairing keratitis. Less frequently, life-threatening disseminated disease (encephalitis and generalized viremia) can also occur, mainly in immunocompromised patients and newborns. After primary infection, HSV persists for life in a latent state in trigeminal or sacral ganglia and, triggered by diverse stimuli, disease recurs in more than 30% of patients up to several times a year. Current therapy with nucleoside analogs targeting the viral polymerase is somewhat effective but limited by poor exposure in the nervous system, and latent infections are not affected by therapy. Here, we report on an inhibitor of HSV helicase-primase with potent in vitro anti-herpes activity, a different mechanism of action, a low frequency of HSV resistance, and a favorable pharmacokinetic and safety profile. Improved target tissue exposure results in superior efficacy in preventing and treating HSV infection and disease in animal models as compared to standard of care. Therapy of primary HSV infections with drug candidate IM-250 {(S)-2-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-N-methyl-N-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)acetamide} not only reduces the duration of disease symptoms or time to healing but also prevents recurrent disease in guinea pigs. Treatment of recurrent infections reduces the frequency of recurrences and viral shedding, and, unlike nucleosidic drugs, IM-250 remains effective for a time after cessation of treatment. Hence, IM-250 has advantages over standard-of-care therapies and represents a promising therapeutic for chronic HSV infection, including nucleoside-resistant HSV.
Collapse
Affiliation(s)
- Christian Gege
- Innovative Molecules GmbH, Leopoldshöher Str. 7, 32107 Bad-Salzuflen, Germany
| | - Fernando J Bravo
- Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center CCHMC, 3333 Burnet Ave., Cincinnati, OH 45229, USA
| | - Nadja Uhlig
- Fraunhofer IZI, Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103 Leipzig, Germany
| | - Timo Hagmaier
- University of Tübingen IFIB, Interfaculty Institute for Biochemistry, Auf der Morgenstelle 34, 72076 Tübingen, Germany
| | | | - Julia Elis
- University of Tübingen IFIB, Interfaculty Institute for Biochemistry, Auf der Morgenstelle 34, 72076 Tübingen, Germany
| | - Anke Burger-Kentischer
- Fraunhofer IGB, Institute for Interfacial Engineering and Biotechnology, Nobelstraße 12, 70569 Stuttgart, Germany
| | - Doris Finkelmeier
- Fraunhofer IGB, Institute for Interfacial Engineering and Biotechnology, Nobelstraße 12, 70569 Stuttgart, Germany
| | - Klaus Hamprecht
- University Hospital of Tübingen UKT, Institute for Medical Virology and Epidemiology of Viral Diseases, Elfriede-Aulhorn-Str. 6, 72076 Tübingen, Germany
| | - Thomas Grunwald
- Fraunhofer IZI, Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103 Leipzig, Germany
| | - David I Bernstein
- Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center CCHMC, 3333 Burnet Ave., Cincinnati, OH 45229, USA
| | - Gerald Kleymann
- Innovative Molecules GmbH, Leopoldshöher Str. 7, 32107 Bad-Salzuflen, Germany. .,University of Tübingen IFIB, Interfaculty Institute for Biochemistry, Auf der Morgenstelle 34, 72076 Tübingen, Germany
| |
Collapse
|
12
|
Caliaro O, Barbani MT, Klenja S, Morfin F, Frobert E, Gorgievski M, Steinlin-Schopfer J, Suter-Riniker F. Phenotypic testing of patient herpes simplex virus type 1 and 2 isolates for acyclovir resistance by a novel method based on real-time cell analysis. J Clin Virol 2020; 125:104303. [PMID: 32163870 DOI: 10.1016/j.jcv.2020.104303] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Revised: 02/17/2020] [Accepted: 02/18/2020] [Indexed: 01/29/2023]
Abstract
BACKGROUND Acyclovir (ACV) is the most commonly used drug for herpes simplex virus (HSV) infection therapy. Prolonged antiviral therapy or prophylaxis in immunocompromised patients may promote the development of drug-resistant strains. Due to the high polymorphism in genes involved in drug resistance, phenotypic methods, although work-intensive, are still required to test drug susceptibility. Real-time cell analysis (RTCA) based methods could offer a rapid and less labor-intensive alternative for phenotypic testing of ACV resistance. OBJECTIVE To investigate the utility of a new RTCA based assay (RTCAA) to test acyclovir susceptibility of HSV clinical isolates. STUDY DESIGN Four reference strains and 93 clinical isolates (60 HSV-1 and 33 HSV-2) were tested by RTCAA. In the presence of ACV concentrations from 2.2 to 140.8 μM, Vero cells were infected with different virus dilutions. IC50 values were calculated by dose-response curve (DRC) with area-under-curve (AUC) method. The reference strains and 22 clinical isolates were additionally tested by dye-uptake assay, and IC50 values of both methods were compared. RESULTS IC50 values from RTCAA and dye-uptake assays were positively correlated (Spearman's rho = 0.897, p < 0.001) and quantitatively agreed (Bland-Altman plot). Based on a cut-off of 4 μM for HSV-1 and 13 μM for HSV-2, 87 isolates were classified as ACV-sensitive and 6 isolates as ACV-resistant. The reference strains showed the expected results of ACV susceptibility. CONCLUSION RTCAA agrees well with the dye-uptake assay. Compared with other phenotypic methods, RTCAA requires less manipulation, reduces the workload and the turnaround time, and appears to be an objective and reliable method to test ACV susceptibility.
Collapse
Affiliation(s)
- Oliver Caliaro
- Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland
| | - Maria Teresa Barbani
- Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland.
| | - Shkipe Klenja
- Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland
| | - Florence Morfin
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et Pathologie Nord, Hospices Civils de Lyon, France; Laboratoire Virpath, Centre International de Recherche en Infectiologie (CIRI) (INSERM U1111 CNRS UMR 5308, ENS, Université de Lyon), Lyon, France
| | - Emilie Frobert
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre de Biologie et Pathologie Nord, Hospices Civils de Lyon, France; Laboratoire Virpath, Centre International de Recherche en Infectiologie (CIRI) (INSERM U1111 CNRS UMR 5308, ENS, Université de Lyon), Lyon, France
| | - Meri Gorgievski
- Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland
| | | | - Franziska Suter-Riniker
- Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001 Bern, Switzerland
| |
Collapse
|